EFFECTS OF A COMBINATION OF BETA CAROTENE AND VITAMIN A ON LUNG CANCER AND CARDIOVASCULAR DISEASE

Background. Lung cancer and cardiovas- cular disease are major causes of death in the United States. It has been proposed that carotenoids and reti- noids are agents that may prevent these disorders. Methods. We conducted a multicenter, randomized, double-blind, placebo-controlled primary prevention trial — the Beta-Carotene and Retinol Efficacy Trial — involv- ing a total of 18,314 smokers, former smokers, and work- ers exposed to asbestos. The effects of a combination of 30 mg of beta carotene per day and 25,000 IU of retinol (vitamin A) in the form of retinyl palmitate per day on the primary end point, the incidence of lung cancer, were compared with those of placebo. Results. A total of 388 new cases of lung cancer were diagnosed during the 73,135 person-years of follow- up (mean length of follow-up, 4.0 years). The active-treat- ment group had a relative risk of lung cancer of 1.28 (95 percent confidence interval, 1.04 to 1.57; P � 0.02), as compared with the placebo group. There were no statis- tically significant differences in the risks of other types of cancer. In the active-treatment group, the relative risk of death from any cause was 1.17 (95 percent confidence interval, 1.03 to 1.33); of death from lung cancer, 1.46 (95 percent confidence interval, 1.07 to 2.00); and of death from cardiovascular disease, 1.26 (95 percent confidence interval, 0.99 to 1.61). On the basis of these findings, the randomized trial was stopped 21 months earlier than planned; follow-up will continue for another 5 years. Conclusions. After an average of four years of sup- plementation, the combination of beta carotene and vita- min A had no benefit and may have had an adverse effect on the incidence of lung cancer and on the risk of death from lung cancer, cardiovascular disease, and any cause in smokers and workers exposed to asbestos. (N Engl J